Form 4: Solid Biosciences CMO Reports Routine Stock Transactions

Solid Biosciences Chief Medical Officer Gabriel Brooks reported the acquisition of common stock from RSU vesting and a subsequent sale to cover tax obligations.

Summary

• Gabriel Brooks, Chief Medical Officer of Solid Biosciences Inc. (SLDB), reported changes in beneficial ownership of common stock.
• On October 18, 2025, 9,750 shares of common stock were acquired upon the conversion of Restricted Stock Units (RSUs).
• Following this acquisition, beneficial ownership increased to 36,714 shares.
• On October 20, 2025, 2,895 shares of common stock were sold at a price of $5.96 per share.
• This sale was made to cover withholding taxes following the vesting of previously granted RSUs and was not a discretionary trade by Dr. Brooks.
• The sale was executed pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024.
• After the sale, beneficial ownership of common stock stands at 33,819 shares.
• The reported beneficial ownership also includes 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025.
• The RSUs were originally granted on October 18, 2023, and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions, including the vesting of restricted stock units and a subsequent non-discretionary sale to cover tax obligations, alongside an Employee Stock Purchase Plan acquisition. These are standard events for executive compensation and do not indicate significant positive or negative discretionary action, leading to a neutral to slightly positive sentiment.

Positives

• Vesting of Restricted Stock Units indicates the fulfillment of employee equity compensation, aligning management interests with shareholders.
• Acquisition of 4,152 shares through the Employee Stock Purchase Plan demonstrates ongoing employee investment in the company.

Negatives

• A portion of shares (2,895) was sold, reducing the insider's direct equity stake, although this was for tax purposes and not a discretionary divestment.

Future Outlook

NA

Management Comments

• The sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024, effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.

Industry Context

NA

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale was for tax purposes and not a discretionary divestment, indicating no change in management's confidence.
• Employees: The vesting of RSUs and participation in the ESPP are positive for employee compensation and alignment with company performance.

Next Steps

• Future vesting events for the remaining Restricted Stock Units on subsequent anniversaries of the October 18, 2023 grant date.

Key Dates

Recommendation

This Form 4 filing details routine, non-discretionary insider transactions related to equity compensation. The acquisition of shares through RSU vesting and the Employee Stock Purchase Plan are positive indicators of ongoing employee alignment and compensation structure. The subsequent sale was explicitly for tax withholding purposes, not a discretionary divestment, and was executed under a pre-arranged plan. Therefore, these transactions do not provide new material information that would warrant a change in investment thesis, leading to a 'hold' recommendation.

Keywords

Solid Biosciences, SLDB, Gabriel Brooks, Form 4, Insider Transaction, Restricted Stock Units, Common Stock, Chief Medical Officer, Equity Compensation